Table 5

Relationship Between IPST and Subsequent 48-H and 30-Day Adverse Ischemic Events in Patients With Post–PCI TIMI Flow Grade 3

Time Point/
Endpoint
IPST
(n = 69)
No IPST
(n = 10,007)
UnadjustedAdjusted
OR (95% CI)p ValueAOR (95% CI)p Value
48 h
 Death/MI/IDR/ARC-ST18 (26.1)429 (4.3)7.88 (4.56–13.60)<0.000110.24 (5.64–18.60)<0.0001
 Death2 (2.9)20 (0.2)14.91 (3.42–65.04)<0.000115.95 (3.38–75.35)0.0005
 ARC Definite ST3 (4.3)23 (0.2)19.73 (5.78–67.32)<0.000120.58 (5.64–75.08)<0.0001
 IDR4 (5.8)43 (0.4)14.26 (4.97–40.88)<0.000115.50 (5.15–46.62)<0.0001
 MI16 (23.2)397 (4.0)7.31 (4.14–12.90)<0.00019.74 (5.21–18.19)<0.0001
30 days
 Death/MI/IDR/ARC-ST20 (29.0)535 (5.4)7.21 (4.26–12.22)<0.00018.85 (5.00–15.65)<0.0001
 Death4 (5.8)79 (0.8)7.72 (2.75–21.70)<0.00018.55 (2.94–24.84)<0.0001
 ARC ST5 (7.2)67 (0.7)11.57 (4.51–29.66)<0.000112.28 (4.64–32.55)<0.0001
 ARC Definite ST4 (5.8)48 (0.5)12.74 (4.47–36.37)<0.000112.94 (4.36–38.39)<0.0001
 IDR5 (7.2)91 (0.9)8.50 (3.34–21.61)<0.00018.87 (3.39–23.17)<0.0001
 MI17 (24.6)424 (4.2)7.38 (4.23–12.86)<0.00019.66 (5.25–17.76)<0.0001

Values are n (%).

Abbreviations as in Tables 1, 2, and 4.

  • Thirty-day efficacy data were unavailable in 18 patients in the no-IPST group. Propensity score based upon age, sex, smoking status, U.S. versus non-U.S. region, race, weight, biomarker, previous MI (stable angina vs. NSTE-ACS vs. STEMI), previous PCI, previous CABG, peripheral artery disease, patient presentation, worst pre-procedure TIMI score, stent type, bifurcation treatment, aspirin dose, number of treated vessels, clopidogrel loading dose (300 vs. 600 mg), infusion duration, bivalirudin received. Missing data were excluded from the modeling.